Related Experiment Video
Updated: Aug 2, 2026
Biomimetic Materials to Characterize Bacteria-host Interactions
Published on: November 16, 2015
Hybrid Biomimetic Membrane Coated Particles-Mediated Bacterial Ferroptosis for Acute MRSA Pneumonia
Huiqun Hu1, Shi Yuan Hua2,3, Xiuhui Lin1
1Department of Infectious Diseases, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Abstract:
Acute methicillin resistant Staphylococcus aureus (MRSA) pneumonia is one of the most frequently seen lung infection diseases with high morbidity and mortality. It is urgent to explore an efficient antibacterial strategy owing to the increase of drug resistance, virulence, and pathogenicity of MRSA. It was found that Fe3O4 can induce ferroptosis in MRSA, but its effect was inhibited by glutathione (GSH) to a certain extent, while cinnamaldehyde (CA) can enhance ferroptosis by consuming GSH. As a bacterial quorum sensing (QS) inhibitor, CA can suppress the QS system and further exert its antibacterial and antibiofilm effects. Here, we developed an Fe3O4-based ferroptosis inducer to promote ferroptosis in MRSA, interrupt the QS, destroy biofilm, and thus effectively treat acute MRSA pneumonia. We used sodium alginate (SA) to wrap Fe3O4 and CA to form particles, and then coated the surface with a hybrid biomimetic membrane composed of an erythrocyte membrane and platelet membrane to obtain lung targeted antibacterial particles (mFe-CA). Under ultrasonic (US) stimulation, mFe-CA can efficiently release Fe3O4 and CA, thereby synergically inducing MRSA death with the characteristics of ferroptosis, including mass ROS production, lipid peroxidation, GSH depletion, and respiratory chain suppression. Furthermore, mFe-CA + US can inhibit the QS system, remove biofilms, and reduce strain virulence. In the mouse model of MRSA pneumonia, mFe-CA + US treatment markedly advanced the survival rate of the mice, reduced the bacterial load in the lungs, and alleviated the inflammatory damage, but there was no obvious toxicity. This study proposes an antibacterial substitute to induce ferroptosis of MRSA, which may provide a foreground for overcoming microbial drug resistance and fighting biofilm-associated infections and also provides a target and theoretical basis for clinical treatment of acute MRSA pneumonia.
Insights
This study developed targeted nanoparticles that induce ferroptosis in MRSA bacteria, effectively treating pneumonia by inhibiting bacterial communication and biofilms. The approach shows promise for overcoming antibiotic resistance.
Area of Science:
- Nanomedicine and Drug Delivery
- Antimicrobial Resistance Research
- Ferroptosis Induction in Bacteria
Background:
- Acute methicillin-resistant Staphylococcus aureus (MRSA) pneumonia presents significant morbidity and mortality due to increasing drug resistance and virulence.
- Existing treatments face challenges from MRSA's defense mechanisms, including glutathione (GSH) which can inhibit ferroptosis, and its quorum sensing (QS) system.
- Iron oxide (Fe3O4) can induce ferroptosis in MRSA, but its efficacy is limited by GSH, while cinnamaldehyde (CA) enhances ferroptosis by depleting GSH and inhibits QS.
Purpose of the Study:
- To develop an Fe3O4-based ferroptosis inducer for synergistic treatment of MRSA pneumonia.
- To enhance antibacterial efficacy by interrupting MRSA quorum sensing (QS) and destroying biofilms.
- To create lung-targeted nanoparticles for efficient delivery and ultrasound-triggered release of therapeutic agents.
Main Methods:
- Fabrication of lung-targeted antibacterial particles (mFe-CA) by encapsulating Fe3O4 and CA within sodium alginate (SA) and coating with a hybrid erythrocyte-platelet biomimetic membrane.
- Ultrasound (US) stimulation to trigger the release of Fe3O4 and CA from mFe-CA particles.
- Evaluation of synergistic effects on MRSA, including ferroptosis induction (ROS production, lipid peroxidation, GSH depletion, respiratory chain suppression), QS inhibition, biofilm removal, and virulence reduction in vitro and in a mouse model of MRSA pneumonia.
Main Results:
- mFe-CA nanoparticles effectively released Fe3O4 and CA under US stimulation, synergistically inducing MRSA ferroptosis and death.
- The treatment significantly inhibited the QS system, eradicated biofilms, and reduced bacterial virulence.
- In vivo studies demonstrated that mFe-CA + US treatment markedly improved survival rates, reduced lung bacterial load, and alleviated inflammation with no obvious toxicity.
Conclusions:
- This study proposes a novel strategy using Fe3O4-based nanoparticles to induce ferroptosis in MRSA, offering a promising alternative to conventional antibiotics.
- The developed mFe-CA + US system effectively targets MRSA pneumonia by combining ferroptosis induction, QS inhibition, and biofilm disruption.
- This approach provides a potential therapeutic avenue for combating microbial drug resistance, biofilm-associated infections, and acute MRSA pneumonia.
